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Cells enter senescence, a state of stable proliferative
arrest, in response to a variety of cellular stresses,
including telomere erosion, DNA damage, and onco-
genic signaling, which acts as a barrier against malig-
nant transformation in vivo. To identify genes control-
ling senescence, we conducted an unbiased screen
for small hairpin RNAs that extend the life span of pri-
mary human fibroblasts. Here, we report that knock-
ing down the chemokine receptor CXCR2 (IL8RB)
alleviates both replicative and oncogene-induced
senescence (OIS) and diminishes the DNA-damage
response. Conversely, ectopic expression of CXCR2
results in premature senescence via a p53-depen-
dent mechanism. Cells undergoing OIS secrete multi-
ple CXCR2-binding chemokines in a program that is
regulated by the NF-kB and C/EBPb transcription
factors and coordinately induce CXCR2 expression.
CXCR2 upregulation is also observed in preneoplas-
tic lesions in vivo. These results suggest that senes-
cent cells activate a self-amplifying secretory net-
work in which CXCR2-binding chemokines reinforce
growth arrest.
INTRODUCTION
Replicative senescence was first described in primary human
fibroblasts that had reached the end of their proliferative life
span in tissue culture (Hayflick and Moorhead, 1961). Senescent
cells undergo an apparently irreversible growth arrest but remain
metabolically active and display characteristic changes in cell
morphology, physiology, and gene expression (Campisi and
d’Adda di Fagagna, 2007). In the fibroblast model, one of the
principal determinants of senescence is the erosion of the telo-
meres that occurs at every cell division. This eventually registers
as DNA damage and triggers cell cycle arrest via activation of the
p53 pathway (d’Adda di Fagagna et al., 2003). The definition of1006 Cell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc.senescence has since been broadened, and it is now accepted
that other forms of DNA damage and cellular stress, whether
caused by the presence of an activated oncogene, unscheduled
DNA replication, oxidative stress, or suboptimal culture condi-
tions can all provoke a senescence phenotype irrespective of
telomere status (Collado et al., 2007). This latter phenomenon
is referred to as oncogene-induced senescence (OIS), prema-
ture senescence or stasis, to distinguish it from classical replica-
tive senescence. However, the implementation of senescence
represents an integrated response to a diverse range of signals.
Despite the experimental focus on tissue culture models, the
wider significance of senescence in vivo has become a matter
of record. The most compelling examples are manifestations of
OIS in benign or premalignant lesions carrying single activated
oncogenes (reviewed in Narita and Lowe, 2005). Senescence
is therefore a first-line defense against potentially dangerous
mutations (Lowe et al., 2004), locking the afflicted cells into a per-
manent state of arrest (Mooi and Peeper, 2006). Progression to
malignancy would correlate with escape from or impairment of
senescence. However, this pivotal mechanism of tumor sup-
pression comes at a cost to the organism, because it sets limits
to the proliferative and regenerative potential of normal tissues.
Cellular senescence is therefore intimately associated with aging
(Collado et al., 2007).
Senescent cells undergo characteristic changes in gene
expression. Some of these changes, such as activation of p53
or the upregulation of the cyclin-dependent kinase (CDK) inhibi-
tors, p16INK4a and p21CIP1, relate directly to the establishment
and maintenance of growth arrest; however, it is striking to note
that senescent cells produce increased amounts of secreted pro-
teins, including extracellular proteases and matrix components,
growth factors, cytokines, and chemokines (Mason et al., 2006;
Shelton et al., 1999). Consequently, senescent cells can alter the
tissue microenviroment and affect neighboring cells through para-
crine signaling. For example, senescent fibroblasts can stimulate
angiogenesis (Coppe et al., 2006), alter differentiation (Parrinello
et al., 2005), and promote growth and tumorigenesis of epithelial
cells (Krtolica et al., 2001). Factors secreted by senescent cells
also contribute to tumor clearance by signaling to the immune sys-
tem (Xue et al., 2007). In addition, it was recently shown that
plasminogen activator inhibitor-1 (PAI-1), a secreted protein that
has been regarded as a marker for senescence, is a transcriptional
target of p53 that directly contributes to the establishment of se-
nescence (Kortlever et al., 2006). Similarly, a study published
while this work was under revision (Wajapeyee et al., 2008) shows
that the insulin-like growth factor binding protein 7 (IGFBP7) me-
diates senescence induced by oncogenic BRAF in normal mela-
nocytes. It is therefore plausible that additional factors secreted
by senescent cells could influence cell growth.
Among the candidates are the multiple chemokines released
by senescent cells. Chemokines are a family of small chemotac-
tic cytokines that mediate communication between different cell
types and have multiple roles in health and disease (Mantovani
et al., 2006). For example, the proinflammatory chemokine IL-
8/CXCL8 modulates endothelial cell migration and promotes an-
giogenesis, tumorigenesis, and metastasis (Yuan et al., 2005).
Ras-dependent secretion of IL-8 enhances tumor progression
by promoting vascularization through paracrine signaling (Spar-
mann and Bar-Sagi, 2004). Chemokines bind to receptors of the
GPCR superfamily. The CXCR2 receptor binds to angiogenic
CXC chemokine family members, containing a glutamic acid-
leucine-arginine motif (ELR+). Thus, in addition to IL-8, CXCR2
binds CXCL1, 2, and 3 (GROa, b, and g), CXCL5 (ENA-78),
CXCL6 (GCP2), and CXCL7 (NAP2), whereas CXCR1 binds
only to GCP2, NAP2, and IL-8.
Here, we report the identification of a small hairpin RNA
(shRNA) targeting CXCR2 in a functional screen for bypass of
replicative senescence in human fibroblasts. In addition, cells
undergoing OIS secrete multiple CXCR2-binding chemokines
in a manner dependent on NF-kB and C/EBPb. These results
suggest that senescent cells activate a self-amplifying secretory
program in which CXCR2 ligands reinforce growth arrest. Impor-
tantly, evidence for elevated expression of CXCR2 in preneo-
plastic lesions, together with a tumor-associated mutation and
loss of expression in advanced cancers, would be consistent
with the view that malignancy reflects escape from senescence.
RESULTS
Downregulation of CXCR2 Expression Extends Cellular
Life Span
Identifying genes that regulate senescence can reveal novel
tumorigenic mechanisms, and several notable examples have
been uncovered in different contexts (Gil et al., 2004; Narita
et al., 2006; Rowland et al., 2005). In the current study, we
used the NKI shRNA library targeting 7914 known genes (Berns
et al., 2004) in a functional screen for extension of the life span of
primary human fibroblasts (Figure 1A). The library is in a 96-well
format, with each well containing three independent shRNAs
against the same gene in the pRetroSuper (pRS) vector. Pooled
DNA from each 96-well plate was used to infect IMR-90 cells. Im-
portantly, we used near-senescent IMR-90 cells (Figure S1A),
which have very limited growth potential, with the expectation
that agents that interfere with senescence would allow the
outgrowth of proliferative colonies.
Among the constructs that extended replicative life span in this
setting (such as shRNAs targeting p53, Rb, and three other con-
structs that we are in the process of validating) was an shRNAagainst CXCR2 (Figure 1B). Retesting confirmed that depletion
of CXCR2 with either of two independent shRNAs delayed senes-
cence in IMR-90 cells but did not immortalize them (Figures 1B
and 1C). Both shRNAs caused almost complete extinction of
CXCR2 expression as judged by quantitative RT-PCR (qRT-
PCR) (Figure 1D) and immunofluorescence (Figure 5C). These
findings are not unique to IMR-90 cells as knock-down of
CXCR2 also extended the life span of other primary cells (WI-38
and human mammary epithelial cells; Figures S1B–S1D).
CXCR2 Depletion Diminishes OIS
and the DNA-Damage Response
Because replicative senescence reflects an amalgam of different
signaling events, we asked whether knockdown of CXCR2 could
also influence OIS. For this purpose, we took advantage of IMR-
90/MEK:ER fibroblasts that express a switchable version of
MEK1, a downstream effector of Ras (Collado et al., 2005).
Upon addition of 4-hydroxytamoxifen (4OHT), these cells un-
dergo growth arrest (Figures S2A and S2B). Depletion of
CXCR2 with shRNA allowed a limited number of cells to evade
MEK-induced arrest (Figure 1E). Consistent results were
achieved with two independent shRNAs. The percentage of cells
incorporating BrdU also increased upon knockdown of CXCR2
as measured 2 days after MEK activation (Figure 1F). Similar
results were observed following transfection of controls and
CXCR2 siRNAs into BJ fibroblasts infected with a retrovirus
encoding H-RasG12V (Figures S2C and S2D).
Because CXCR2 influences oncogene-induced and replica-
tive senescence, and DNA-damage response signaling plays
a core role in both (Campisi and d’Adda di Fagagna, 2007), we
investigated whether CXCR2 modulates the DNA damage
checkpoint. To this end, we exposed IMR-90 cells infected
with a control or an shRNA vector targeting CXCR2 to X-irradia-
tion. Whereas control cells encountered a DNA damage check-
point, as shown by diminished BrdU incorporation, cells with
either CXCR2 or p53 knocked down did not arrest significantly
(Figure 1G). Moreover, upon CXCR2 knockdown, ATM activation
was impaired as indicated by reduced number and decreased
intensity of DNA-damage response (DDR) foci containing the
phosphorylated active form of ATM in irradiated cells (Figure 1H).
Similarly, pST/Q antibodies recognizing phosphorylated ATM
and ATR targets gave reduced signals in cells depleted of
CXCR2 expression (Figure S2E). These results are consistent
with CXCR2 affecting senescence by influencing the activation
of the DNA damage checkpoint.
Premature Senescence Induced by Expression
of CXCR1 or CXCR2 Is Dependent on p53
To complement the findings with CXCR2 shRNAs, we next asked
whether ectopic expression of CXCR2 or its paralog CXCR1
would impair cell proliferation. When viruses expressing
CXCR1 or CXCR2 (Figure 2A) were used to infect IMR-90 cells,
both caused retarded growth culminating in premature senes-
cence (Figure 2B). CXCR2 overexpression also slowed the
growth of WI-38 and human mammary epithelial cells (Figure S3).
Although in human fibroblasts the CXCR2-induced arrest was
not as dramatic as that caused by H-RasG12V, the cells showed
reduced incorporation of BrdU (Figure 2C) and displayedCell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc. 1007
Figure 1. Depletion of CXCR2 Extends Cellular Life Span and Blunts Oncogene-Induced Senescence
(A) Outline of the genetic screening for identifying shRNAs extending life span of IMR-90 cells.
(B) IMR-90 cells were infected with pRS, pBabe, and shCXCR2-1 after selection growth curves were performed.
(C) Microphotographs showing the effect of two independent constructs targeting CXCR2 (1 and 4) over growth and morphology of IMR-90 cells.
(D) Confirmation of the levels of CXCR2 knockdown by qRT-PCR. Error bars represent standard deviation.
(E) IMR-90/MEK:ER cells were infected with the indicated vectors, selected and 105 cells seeded per 10 cm dish. Next day, 100 nM 4-OHT was added. After 15
days, plates were fixed and stained with crystal violet. Plot represents the relative cell number normalized to pRS-infected cells. For clarity, the scale has been
split. Error bars represent the standard deviation.1008 Cell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc.
characteristic features of senescence. For example, the propor-
tion of cells staining positively for senescence-associated b-ga-
lactosidase (b-Gal) activity and displaying senescence-associ-
ated heterochromatin foci was elevated in cultures transduced
with CXCR1 or CXCR2 compared with controls (Figure 2D). Sim-
ilarly, although the overall percentages were small, a higher pro-
portion of the CXCR2-transduced cells displayed DDR foci. In
addition, the number of DDR foci and their intensity was more el-
evated in cells expressing CXCR2 (Figure 2E).
As the DNA damage pathway activates p53, we explored the
role of p53 in CXCR2-mediated arrest by genetic means. To
this end we analyzed the effects of CXCR2 in WI-38 human fibro-
blasts in which p53 or pRb functions were disrupted using the
HPV E6 and E7 proteins, respectively. The data confirm the im-
portance of p53 but imply that the Rb pathway is also involved
in establishing the CXCR2-induced arrest in human cells (Fig-
ure 2F). Consistent with the role of p53, depletion of CXCR2 in dif-
ferent primary cells resulted in reduced levels of p53, p21CIP1, and
other p53 targets as assessed via western blot analysis (Fig-
ure S4). To substantiate these findings, we took advantage of
mouse embryo fibroblasts (MEFs) genetically deficient for p53,
p16Ink4a/p19Arf, or p21Cip1. Infection of wild-type MEFs (passage
1) with retroviruses encoding human CXCR1 or CXCR2 caused
a rapid growth arrest, whereas control cells continued proliferat-
ing (Figure 2G). If anything, the effects of CXCR1 or CXCR2 were
more profound than in IMR-90 cells. Similar results were obtained
when the assays were performed in Ink4a/Arf/ or p21/ MEFs
and the cells arrested with the morphological characteristics of
senescence (Figure S5). In contrast, p53/ MEFs were refrac-
tory to CXCR1 or CXCR2 expression and continued proliferating
(Figure 2G). Interestingly, in p53/ MEFs, ectopic expression of
CXCR2 resulted in cells that lost contact inhibition and produced
anchorage-independent colonies, although smaller than with
H-RasG12V (Figure S5F). Taken together, these results suggest
that CXCR2-induced senescence is p53-dependent.
Coordinated Upregulation of CXCR2 and Their
Ligands during Senescence
Having shown that altering CXCR2 expression can either delay
or promote senescence, we next asked whether the endoge-
nous levels of CXCR2 change during senescence. In human
fibroblasts, CXCR2 expression was low (undetectable by immu-
nofluorescence) at early and middle passage but increased
during replicative senescence, as detected by qRT-PCR and im-
munofluorescence (Figures 3A and 3B and Figure S6). Similarly,
the levels of CXCR2 messenger RNA were approximately 6-fold
higher in cells undergoing H-RasG12V-induced senescence com-
pared with controls (Figure 3C). Upregulation of CXCR2 following
H-RasG12V expression was also demonstrable by immunofluo-
rescence (Figure 3D).If the receptor is upregulated, it was important to know whether
any of the CXCR2-binding chemokines were expressed during
OIS. To this end, we used antibody arrays (Ray Biotech) to monitor
the levels of 90 secreted factors (Figure S7) in the medium from
control IMR-90/LXSN and IMR-90/MEK:ER cells treated with
and without 100nM4OHT for 72 hr. Approximately12-14secreted
factors were significantly expressed during OIS, including the
proinflammatory cytokines IL-6 and IL-1a (Figure 3E). This is
consistent with previous studies (Mason et al., 2006). Of the 37
chemokines represented on the arrays, only 8 showed elevated
expression in cells undergoing OIS (Figure 3E). This could be an
overestimate, because the array did not have an antibody that dis-
criminates GROb and GROg from GROa. Interestingly, this set in-
cluded all CXCR2 ligands except GCP2. Because antibody arrays
are semiquantitative, and have a limited dynamic range (saturated
for the IL-8 and GROa, b, g antibodies), we performed qRT-PCR
and enzyme-linked immunosorbent assay (ELISA) to measure
IL-8 and GROa. The results from the ELISAs showed that 48 hr
after treatment of IMR-90/MEK:ER, cells with 4OHT, secretion of
IL-8, and GROa increased dramatically (Figures 3F and 3G). In ac-
cordance with published reports (Ancrile et al., 2007; Sparmann
and Bar-Sagi, 2004), IL-8 and GROa also increased in response
to MEK activation, even in the absence of senescence (Figure S8).
Analyses using qRT-PCR confirmed a significant increase of all
CXCR2 ligand transcripts, including GCP2, in cells undergoing
OIS, with a more prominent induction of IL-8 and ENA-78 (Fig-
ure 3H). These data indicated a coordinated upregulation of
CXCR2 and its ligands at senescence, occurring at the RNA level.
NF-kB and C/EBPb Regulate the Expression
of CXCR2 Ligands during OIS
To elucidate the signaling pathways involved in the induction of
IL-8 and other CXCR2 ligands during OIS, we first asked whether
different chemical inhibitors could block their production. As
a positive control, treatment with the MEK inhibitor PD98059
prevented the induction of IL-8 following addition of 4OHT, in
IMR-90/MEK:ER cells (Figure 4A). Inhibition of p38 MAPK with
10 mM SB202190 or inhibition of IkB kinases with 10 mM BAY
11-7082 also blunted the upregulation of IL-8 (Figure 4A). Using
antibody arrays, we observed that the induction of IL-8, most
CXCR2 ligands, and other chemokines depended on NF-kB (Fig-
ure 4B). Bioinformatic predictions showed that sites for NF-kB
and C/EBP, among others, were present in the promoters of
most CXCR2 ligands (data not shown).
Because of precedents linking Ras and MEK to the activation of
NF-kB and C/EBPb (Finco et al., 1997; Nakajima et al., 1993), and
the role of C/EBPb in OIS (Sebastian et al., 2005), we focused on
these factors and asked whether they were being activated dur-
ing OIS. Analysis of NF-kB function showed that there is active
NF-kB in the nucleus upon MEK induction (Figure 4C). In addition,(F) IMR-90/MEK:ER cells were infected with the indicated viruses. After selection, cells were left untreated or treated with 100 nM 4OHT. After 5 days, a 16 hr pulse
of BrDU was given, the cells were fixed, and BrdU was quantified.
(G) IMR-90 cells infected with control vector or shCXCR2-1 were irradiated with 5 Gy and pulsed with BrdU 1 hr after irradiation for 8 hr. Later, BrdU-positive cells
were quantified and normalized to the respective control cells. Error bars represent the standard deviation.
(H) Same cells as in (G) were analyzed by immunofluorescence using ATM pS1981 antibody.
The experiments shown in (B-F) were performed independently at least three times. Experiments shown in (G) and (H) were performed independently twice with
similar results.Cell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc. 1009
Figure 2. Ectopic Expression of CXCR2 or CXCR1 Causes Premature Senescence Dependent of p53
(A) MEFs were infected with vectors expressing human CXCR1 or CXCR2 or controls. Expression of human CXCR1 (upper panel) or CXCR2 (lower panel) was
assessed via immunofluorescence.
(B) IMR-90 cells were infected at passage 17 with the indicated vectors, selected, and growth curves were performed.
(C) Percentage of BrdU-positive cells in IMR-90 cells infected with the vector or overexpressing CXCR2.
(D) Percentage of the indicated cells positive for SAb-Gal activity and senescence-associated heterochromatin foci (SAHFs).
(E) Percentage of gH2AX-positive cells in IMR-90 cells infected with the vector or overexpressing CXCR2.
(F) Human diploid fibroblasts infected with the indicated vectors were seeded in 10 cm dishes. The plates were fixed 10–15 d after seeding and stained with
crystal violet. Crystal violet was extracted and quantified.
(G) MEFs of the indicated genotypes were infected with pBabe, CXCR1, CXCR2, and H-RasG12V retroviruses, selected, and 105 cells were seeded per 10 cm
dishes. The plates were fixed 10–15 d after seeding and were stained with crystal violet.
The experiments showed were performed independently at least twice with similar results.1010 Cell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc.
Figure 3. Coordinated Upregulation of CXCR2 and Their Ligands during Senescence
(A) Analysis of CXCR2 transcript levels during serial passage of IMR-90 cells. Error bars represent the standard deviation.
(B) IMR-90 cells at the indicated passages were fixed and subjected to CXCR2 immunofluorescence.
(C) Analysis via qRT-PCR of CXCR2 transcript levels in IMR-90 cells infected with pBabe or H-RasG12V. Error bars represent the standard deviation.
(D) IMR-90 cells infected with pBabe or H-RasG12V were subjected to CXCR2 immunofluorescence.
(E) Antibody arrays were used to measure the secretion of 90 factors by IMR-90/LXSN or IMR-90/MEK:ER cells grown in DMEM 0.5% fetal bovine serum and
treated with (+) or without () 100 nM 4OHT for 72 hr. The arrays were scanned and quantified; the levels were normalized to internal positive controls present in
each membrane and split into four groups (0%-25%; 25%-50%; 50%-75%; 75%-100%, or more) referred to the positive control expression in order to represent
the semiquantitative results as a heat map. Presented are the factors upregulated during OIS. CXCR2-binding chemokines are underlined.
(F, G) The amount of IL-8 (F) or GROa (G) secreted by IMR-90/MEK:ER or control cells treated with or without 100 nM 4OHT during 48 hr was quantified via ELISA.
The experiments were performed independently at least four times with similar results.
(H) The levels of CXCR2 ligands expressed in IMR-90 cells infected as indicated were quantified via qRT-PCR. Similar results were observed in three independent
experiments.the expression of two key NF-kB transducers, RelA and IKKb in-
creases during OIS (Figure 4D and Figure S9D). To substantiate
the role of NF-kB, we designed two shRNAs targeting RelA (Fig-
ure 4E). Depletion of RelA decreased the production of IL-8, and
most CXCR2 ligands during OIS (Figures 4F and 4G). Finally, we
also detected by chromatin immunoprecipitation binding of RelA
to the promoters of IL-8 and GROg, suggesting that the observed
regulation of these chemokines by NF-kB was direct (Figure 4H).Besides NF-kB, the activation of C/EBPb also increased in re-
sponse to MEK induction and the C/EBPb messenger RNA itself
was also upregulated during OIS (Figure S9). Depletion of
C/EBPb using shRNA constructs reduced the induction of IL-8,
GROa, and NAP2 during OIS (Figures S10A and S10B). The
effect over IL-8 secretion was confirmed using independent
siRNAs targeting C/EBPb (Figure S10F). Interestingly, binding
sites for C/EBPb and NF-kB are present in neighboring positionsCell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc. 1011
in the IL-8 and GROa promoters and these transcription factors
regulate synergistically IL-8 and GROa during viral infection and
stress (Hoffmann et al., 2002).
CXCR2 Is Activated in Senescence
As CXCR2 ligands are upregulated during senescence, we ana-
lyzed their functional involvement in the process. We generated
retroviral vectors to ectopically express IL-8 and GROa. Signifi-
cantly, expression of IL-8 or GROa reduced proliferation of late
passage IMR-90 cells (Figure 5A and Figures S11A and S11B).
Conversely, depletion of IL-8 expression using an shRNA (Fig-
ure S11C) extended the life span of IMR-90 cells (Figure 5B).
To investigate whether IL-8 depletion affected CXCR2 activa-
tion, we analyzed the subcellular localization of CXCR2. The lo-
cation of CXCR2 in endosomes can be considered as a surrogate
marker for CXCR2 activation (Sai et al., 2006 and Figure S12) and
correlates with other effects caused by CXCR2 activation such
as production of reactive oxygen species (ROS) (Figure S13).
CXCR2 localization in endosomes diminished when comparing
control cells with cells expressing sh-IL-8 (from 71% to 25%)
(Figure 5C), suggesting that sh-IL-8 extends cellular life span
by restraining CXCR2 activity.
Knockdown of either IL-8 or GROa using shRNAs alleviated
OIS in IMR-90 expressing MEK:ER as measured by enhanced
BrdU incorporation (Figure 5D) or rescue of cell growth (data
not shown). Although the effects were relatively modest (as
with CXCR2 knockdown) they were consistently observed with
two independent shRNAs against IL-8 or GROa (Figure 5D and
data not shown). Interestingly, antibodies neutralizing IL-8 and
GROa also alleviated OIS, as did treatment with a chemical
CXCR2 inhibitor (SB 225002) (Figure 5E). This suggests that
secreted CXCR2 ligands can reinforce senescence. In cells
undergoing H-RasG12V-triggered OIS, CXCR2 was mainly in en-
dosomes (70%), indicative of activation (Figure 5F), whereas
CXCR2 localized mainly in the membrane following treatment
with either SB 225002 or with neutralizing antibodies targeting
IL-8 and GROa. Treatment with an MEK inhibitor that downregu-
lates the expression of IL-8 and other ligands (Figure 5F) resulted
Figure 4. NF-kB Controls the Expression of
CXCR2 Ligands during Senescence
(A) IMR-90/MEK:ER cells were treated with
SP600125 (JNK inhibitor, 10 mM), PD98059 (MEK
inhibitor, 20 mM), SB202190 (p38 inhibitor, 10 mM),
BAY 11-7082 (IKK inhibitor, 10 mM), LY294002
(PI3K inhibitor, 2 mM), or SB225002 (CXCR2 inhib-
itor, 200 nM). One hour later, 100 nM of 4OHT or an
equivalent volume of vehicle was added. Twenty-
four hours later, supernatants were collected and
IL-8 was measured via ELISA. The experiment
was performed independently three times, and
the mean is represented. Error bars represent
the standard deviation.
(B) IMR-90/MEK:ER cells were treated with 10 mM
BAY 11-7082 or vehicle (control). One hour later,
100 nM of 4OHT was added. Seventy-two hours
later, supernatants were collected and used to
probe antibody arrays. The values for the different
chemokines present in the control membrane
were taken as 100%.
(C) Nuclear extracts from IMR-90/LXSN or IMR-
90/MEK:ER left untreated or treated with 100 nM
4OHT for 72 hr were used to measure NF-kB activ-
ity as explained in Experimental Procedures. The
experiment represented triplicate samples, and
two independent experiments were performed
with similar results. Error bars represent the stan-
dard deviation.
(D, E) IMR-90 cells were infected with the indicated
vectors, and expression of RelA was analyzed via
qRT-PCR.
(F) IMR-90/MEK:ER cells were infected with the in-
dicated vectors. Cells were selected, seeded, and
switched to 0.5% fetal bovine serum, and 24 hr
later 100 nM 4OHT was added. Supernatants
were collected 24 hr after 4OHT treatment, and
IL-8 was measured via ELISA.
(G) Supernatants collected at 72 hr from the same
experiment as in (F) were used to probe antibody
arrays.
(H) Chromatin immunoprecipitation analyzing the
binding of RelA/p65 to the promoter of CXCR2 ligands. Specific binding is represented as the ratio of p65 versus Histone H3 binding and normalized to the binding
in control cells. Similar results were obtained in two independent experiments. Error bars represent the standard deviation.1012 Cell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc.
Figure 5. Role for CXCR2 Ligands in Mediating Senescence
(A) IMR-90 cells were infected with the indicated retroviruses. After selection, 105 cells were seeded in a 10 cm dish, and after 15 days plates were fixed and
stained with crystal violet that was extracted and quantified. Error bars represent the standard deviation.
(B) IMR-90 cells were infected with the indicated retroviruses after selection growth curves were performed.
(C) IMR-90 cells infected with the indicated vectors were subjected to CXCR2 immunofluorescence at late passage. The percentage of cells showing preferential
localization of CXCR2 in endosomes as explained in Figure S12 is shown.
(D) IMR-90/MEK:ER cells were infected with the indicated retrovirus. After selection, cells were plated and treated with vehicle or 100 nM 4OHT. Forty-eight hours
after treatment, cells were pulsed with BrdU for 16 hr, and BrdU incorporation was quantified. Similar results were obtained in three independent experiments.
(E) IMR-90/MEK:ER cells were treated as indicated. Final concentrations added were: 10 mg/ml for each IL-8- and GROa-neutralizing antibody (Neutr. Abs), 200
nM SB225002 (SB), and 20 mM PD98059 (PD). Twenty-four hours after treatment, cells were pulsed with BrdU for 16 hr and BrdU incorporation was quantified.
(F) IMR-90 cells infected with RasV12 and treated as indicated were subjected to CXCR2 immunofluorescence. Concentrations added were as in (E) and they
were kept for 4 hr. The percentage of cells showing preferential localization of CXCR2 in endosomes as explained in Figure S12 is shown.in strong localization of CXCR2 in the cytoplasmic membrane.
These results show a clear correlation between CXCR2 activa-
tion and induction of senescence. In addition, the ability of
neutralizing antibodies to alleviate OIS suggests that secreted
CXCR2 ligands may have a role in senescence reinforcement.
CXCR2 Expression Is Elevated in Preneoplastic Lesions
The upregulation of CXCR2 and their binding chemokines during
OIS prompted us to ask whether the components of the CXCR2
network, CXCR1, CXCR2 and their ligands, might also be upre-
gulated in preneoplastic lesions associated with senescent cells.
For example, topical treatment of mouse skin with DMBA/TPA
leads to the appearance of benign papillomas. These premalig-nant lesions display a high proportion of senescent cells and the
expression of markers of senescence, such as Arf or Dcr2 is
elevated compared to control skin (Collado et al., 2005 and Fig-
ure 6A). The expression of CXCR2 and its ligands was also
significantly increased in papillomas (Figure 6A). Interestingly,
IL-6 and its receptor are also upregulated in papillomas
(Figure S14), suggesting that a coordinated expression of recep-
tor-ligand pairs could be a recurrent theme during senescence.
To extend these analyses to a clinical setting, we monitored
CXCR2 expression in a panel of 30 prostate intraepithelial
neoplasia (PIN) samples by immunohistochemical staining. Pre-
neoplastic PIN lesions are enriched in senescent cells (Chen
et al., 2005, and Figure S15A) and their progression to malignantCell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc. 1013
Figure 6. CXCR2 Expression Is Elevated in Premalignant Lesions
(A) qRT-PCR analysis of Arf, Dcr2, Cxcr2, Cxcl1, Cxcl2, and Cxcl5 transcript levels in samples from normal skin (NS) or DMBA-TPA-induced mouse papillomas
(P). The p values correspond to a nonparametric, unpaired t test. *p < 0.05. **p < 0.001. ***p < 0.0001.
(B) Immunohistochemistry showing CXCR2 staining in sections from prostate. PIN, prostate intraepithelial neoplasia; A/N glands, atrophic/normal glands.
(C) CXCR2 staining. In 29/30 cases, the stain in PIN glands was above that in normal glands, generally negative. In four cases were PCa was present in the same
sections, it was negative for CXCR2 staining or weakly positive. In 8/14 cases analyzed, we observed that PIN glands stain more intensely than the PCa in the
same section, in 2/14 the CXCR2 staining was similar in PCa and PIN, with the rest of cases showing heterogeneous CXCR2 staining.prostate adenocarcinoma (PCa) is thought to require cooperat-
ing mutations that allow bypass of senescence. Epithelial cells
from normal prostate glands did not stain positive for CXCR2
expression (only scattered cells, likely of neuroendocrine origin,
did). In contrast, the PIN lesions were positive for CXCR2. In
about a third of these cases, the staining was relatively low but
consistently above normal gland levels (Figures 6B and 6C).
When glands displaying PCa were present, they stained for
CXCR2 less intensely than PIN (8/14) (Figures 6B and 6C). We
also analyzed the expression of CXCR1 (Figures S15B and
S15C) with qualitatively similar results. In general, the levels of
CXCR1 staining were higher in PIN than that of CXCR2, but its
distribution was more heterogeneous among glands and even
inside an individual gland.
A CXCR2 Mutant Present in Lung
Adenocarcinoma Cells Alleviates OIS
Reasoning that further proof for a pathological role for CXCR2 in
senescence in vivo would come if inactivating mutations in
human tumors existed, we searched the COSMIC database
(http://www.sanger.ac.uk/genetics/CGP/cosmic/). An analysis
of 40 cancer cell lines identified a point mutation in CXCR2
(G354W) in the lung adenocarcinoma cell line NCI-H1395. To in-1014 Cell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc.vestigate whether the substitution affects CXCR2 function, we
expressed the CXCR2G354W allele in IMR-90 cells. Immunofluo-
rescence and FACS showed that steady-state levels of the
CXCR2G354W allele were higher than those of CXCR2 wild-type
(Figure 7A and Figures S16A and S16B). Under standard tissue
culture conditions, the CXCR2G354W allele localized mainly in
the membrane, while CXCR2 wild-type was present mostly in en-
dosomes (Figure 7B). Interestingly, when IMR-90 cells express-
ing CXCR2 wild-type were treated with a CXCR2 antagonist that
prevents its internalization and recycling, the levels and localiza-
tion of CXCR2 wild-type resembled those of the CXCR2G354W al-
lele (Figure 7A). Moreover, stimulation of IMR-90 cells with IL-8 or
GROa failed to internalize CXCR2G354W (Figure 7B) and did not
increase ROS levels, contrary to cells expressing CXCR2 wild-
type (Figure S13). These results are consistent with defective
internalization of the CXCR2G354W allele that results in dimin-
ished signaling.
Next, we compared the effects of CXCR2G354W and CXCR2WT
on cell proliferation. Whereas IMR-90 cells expressing wild-type
CXCR2 suffered premature senescence, cells expressing the
CXCR2G354W allele did not (Figure 7C). Similar results were
obtained in MEFs (Figures S16C and S16D). Interestingly, the
NCI-H1395 cell line bears a mutation in B-RAF (G469A) that
Figure 7. A CXCR2 Mutation Present in Lung Adenocarcinoma Alleviates Senescence
(A) The levels of CXCR2 in IMR-90 cells infected with the indicated vectors were analyzed via immunofluorescence. When indicated, cells were treated for 16 hr
with 200 nM SB225002.
(B) CXCR2 immunofluorescence in IMR-90 cells infected with CXCR2 wild-type and CXCR2G354W treated as indicated. Cells were serum starved overnight and
treated with 100 ng/ml IL-8 or 250 ng/ml GROa for 1 hr. The percentage of cells showing preferential localization of CXCR2 in endosomes as explained in
Figure S12 is shown.
(C) IMR-90 cells were infected at passage 17 with the indicated retroviral vectors, selected, and growth curves were performed.
(D) IMR-90/MEK:ER cells were infected with the indicated retrovirus. After selection, cells were plated and treated with control vehicle or 100 nM 4OHT. Forty-
eight hours after treatment, cells were pulsed with BrdU for 16 hr, and BrdU incorporation was quantified. Three independent experiments yielding equivalent
results were performed.renders it constitutively active (Wan et al., 2004) and could
induce OIS. To investigate the effect of the G354W mutation
on OIS, we infected IMR-90/MEK:ER cells with the CXCR2G354W
allele. Expression of this allele alleviated OIS to a similar extent
as shRNAs targeting CXCR2 (Figure 7D). It is tempting to spec-
ulate that the presence of the CXCR2G354W allele might have
allowed the lung adenocarcinoma NCI-H1395 cells to bypass
BRAFG469A-induced OIS.
DISCUSSION
The significance of senescence in physiological and pathological
settings, such as aging and cancer, has gained firm ground. In
recent years, multiple studies have shown that senescent cells
accumulate in premalignant lesions and during aging (Collado
et al., 2007). It is therefore important to learn more about the
mechanisms underpinning the establishment and maintenance
of senescence and the consequent behavior of the senescent
cell. Despite steady progress in probing the roles of the p53
and Rb pathways, little is known about other mechanisms that
might contribute to the senescent phenotype.
One of the characteristic features of senescent cells is that they
produce increased quantities of various secreted proteins. Fac-tors secreted by senescent cells exert multiple effects on neigh-
boring epithelial cells (Coppe et al., 2006; Krtolica et al., 2001;
Parrinello et al., 2005) and direct the immune system to clear
a senescent lesion (Xue et al., 2007). Secreted factors such as
PAI-1 (Kortlever et al., 2006) and IGFBP7 (Wajapeyee et al.,
2008) also contribute to senescent growth arrest. Here we
show that fibroblasts undergoing OIS upregulate the chemokine
receptor CXCR2 and its ligands, and that by experimentally ma-
nipulating these levels, it is possible to promote or delay senes-
cence. This suggests the existence of a positive feedback loop
involving chemokine signaling via CXCR2 that acts to reinforce
senescence. Similar results are reported in an accompanying pa-
per by Kuilman et al. (2008; this issue ofCell), which shows that IL-
6 is expressed by senescent cells and is required for the induction
and maintenance of cell cycle arrest of cells exposed to onco-
genic stress. The effects exerted by CXCR2 in vitro, though mod-
est, are conserved across a wide range of primary cell types. The
physiological relevance of CXCR2 signaling during OIS is further
backed by our observations in preneoplastic lesions and tumors
(Figures 6 and 7).
Two of the prominent ligands for CXCR2 are IL-8 and GROa.
IL-8 has multiple paracrine and autocrine effects. As a paracrine
agent, it modulates endothelial cell migration and isCell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc. 1015
a chemoattractant for neutrophils. As an autocrine agent, IL-8
promotes the growth of different cancer cell types. Elevated ex-
pression of IL-8 is observed in experimental settings (Sparmann
and Bar-Sagi, 2004) and human malignancies, and has been
linked to increased angiogenesis and vascularization, metastatic
spread, and poor prognosis (Yuan et al., 2005). Similar infer-
ences have been drawn for GROa, first described as an auto-
crine factor stimulating the growth of melanoma cells (Bordoni
et al., 1990). Although these growth-promoting functions appear
at odds with the growth arrest that we observe in primary cells,
such paradoxical behavior has become common.
The classic example of a protein having pro-oncogenic or anti-
oncogenic activity depending on cellular context is H-RasG12V
(Serrano et al., 1997), but similar conclusions have been drawn
for HMGA (Narita et al., 2006) and KLF4 (Rowland et al., 2005).
By analogy, overstimulation of CXCR2 activity, by increasing
the levels of the receptor or its ligands, or as a consequence of
upstream oncogenic signals, elicits a senescence phenotype
in primary cells. In cells in which the senescence machinery is
compromised, such as p53/ MEFs (Figure 2G and Figure S5)
or immortal NIH 3T3 cells (Burger et al., 1999), autocrine CXCR2
signaling becomes pro-oncogenic, enabling anchorage indepen-
dent growth. As shown with other oncogenes (eg H-RasG12V,
Serrano et al., 1997) the requirements for canceling CXCR2-in-
duced senescence in human cells are more strict. Turning this
around, cells in which CXCR2 signaling has been compromised
are also less able to engage senescence in response to onco-
genic signals from Ras or MEK.
The DNA-damage response is central to replicative and onco-
gene-induced senescence. Our data show that expressing
CXCR2 increases DNA damage, and conversely its depletion
results in diminished activation of the DDR. How CXCR2 activity
influences the DDR and p53 would need further investigation,
but we hypothesize that an increase in ROS levels (Figure S13)
might be involved. ROS levels can influence OIS (Lee et al.,
1999) and telomere-induced DNA damage during replicative
senescence (Passos et al., 2007). Therefore, CXCR2 seems to
control senescence via a different mechanism that other se-
creted factors such as PAI-1, which regulates the PI3-kinase
pathway (Kortlever et al., 2006), or IGFBP7, which impacts on
MAPK signaling (Wajapeyee et al., 2008).
Another interesting issue is whether CXCR2 ligands could
induce senescence in a paracrine fashion. Our experiments
indeed showed that neutralizing antibodies against IL-8 and/or
GROa alleviated OIS. Given the observed increase in the expres-
sion of both CXCR2 and its ligands during senescence, we
hypothesize that secreted CXCR2-binding chemokines mainly re-
inforce senescence in cells that have already upregulated CXCR2
as opposed to spreading senescence to proliferative neighboring
cells. We cannot discount that upregulation of CXCR2 and its li-
gands could act in part through an intracellular or autocrine acti-
vation of the receptor. Whether secreted CXCR2 ligands contrib-
ute to senescence in normal cells by acting in a paracrine way, as
it has been described for IGFBP7, will require further investiga-
tion. Overall, the ability of CXCR2-binding chemokines to rein-
force senescence and to promote clearance of incipient tumors
via recruitment of immune cells (as shown by Xue et al., 2007)
argues for a potent tumor suppressor effect for CXCR2 signaling.1016 Cell 133, 1006–1018, June 13, 2008 ª2008 Elsevier Inc.The extent to which IL-8, GROa, and other CXCR2-binding
chemokines are upregulated during replicative and particularly
oncogene-induced senescence is striking. The IL-8 gene con-
tains an enhancer that can be bound cooperatively by NF-kB
and C/EBPb, and our analyses suggest a role for both in regulat-
ing IL-8 and other CXCR2 ligands during OIS. NF-kB is activated
in response to Ras or MEK (Finco et al., 1997), as is C/EBPb (Na-
kajima et al., 1993). Although it is presently unclear how CXCR2
expression is controlled during the implementation of senes-
cence, it is also an NF-kB target (Maxwell et al., 2007). Overall,
the regulation of both CXCR2 and its ligands seems key for rein-
forcing senescence. Taken together, the combined data impli-
cate NF-kB and C/EBPb in controlling the secretory program
associated with oncogene-induced senescence.
CXCR2 is upregulated not only in senescent cells in culture but
also in preneoplasic lesions in vivo. We illustrate this point with
DMBA/TPA-induced papillomas in the mouse, and in PIN, re-
garded as precursor of human PCa (Figure 6). Although it would
clearly be interesting to extend these analyses to additional tumor
types, mining of published datasets presents a mixed picture. El-
evated levels of CXCR2 transcripts have been reported in lung
carcinoid tissue (Bhattacharjee et al., 2001) while lower levels of
CXCR2 expression in head and neck squamous cell carcinomas
coexist with upregulation of most CXCR2 ligands (Ginos et al.,
2004; Toruner et al., 2004). The second would be consistent
with the idea that increased levels of CXCR2 are associated
with senescence in premalignant lesions and that more advanced
cancers develop as a result of failure of senescence. Loss of
CXCR2 expression could be viewed either as evidence for or as
a causal factor in the bypass of senescence. Support for the latter
comes from the identification of a CXCR2 inactivating mutation in
the lung adenocarcinoma cell line NCI-H1395. Although we have
to caution that only a single cell line with mutations in CXCR2 has
so far been reported in COSMIC, we still believe that it provides
an important proof of principle. Expression of the CXCR2G354W
allele not only does not induce premature senescence unlike
CXCR2 wild-type, but also alleviates OIS.
In summary, we report here that the chemokine receptor
CXCR2 and many of its ligands are upregulated during senes-
cence. They form part of a chemokine network reinforcing
growth arrest in a p53-dependent manner. The relevance of
this network is unveiled as different preneoplastic lesions show
enhanced expression of CXCR2, and its downregulation or mu-
tation may be necessary for progression of some cancer types.
EXPERIMENTAL PROCEDURES
Cell Culture, Retroviral Infection, and Growth Curves
293T, BJ, WI-38, IMR-90, and NCI-H1395 cells (ATCC) were maintained as
indicated. Retrovirus production and infection, growth curves, SA-b-Gal anal-
ysis, and isolation and maintenance of MEFs were performed as described
previously (Gil et al., 2004). MEFs of different genotypes were obtained from
S. Lowe (Cold Spring Harbor Laboratories, USA).
Genetic Screening
IMR-90 cells (passage 20; see Figure S1A), were infected with the appropriate
controls or pools of constructs of the NKI RNAi library (Berns et al., 2004). Con-
structs allowing bypassing senescence were identified by PCR as described in
the Supplemental Experimental Procedures.
Retroviral Vectors
Complementary DNAs for human IL-8, GROa, CXCR1, and CXCR2 were
cloned via PCR in pBabepuro or pMarX IV puro. The CXCR2G354W mutant
was generated via PCR using a primer that incorporates the mutation and
cloned into pBabepuro. Retrovirus encoding shRNAs were constructed as
described previously (Gil et al., 2004).
Immunofluorescence
Immunofluorescence was performed using confocal laser scanning micros-
copy (TCS SPI system, Leica). Antibodies used were: CXCR1 (555937; BD),
CXCR2 (555932; BD), gH2AX (05-636; Upstate), pST/Q (2851; Cell Signaling),
and ATM pS1981 (200-301-400; Rockland). Senescence-associated hetero-
chromatin foci were visualized with DAPI staining.
Quantitative RT-PCR and Taqman Analysis
Total RNA was extracted using the RNeasy minikit (QIAGEN). Complementary
DNAs were generated using Superscript II (GIBCO). PCR reactions were per-
formed on an Opticon 2 (Bio-Rad) using SYBR Green PCR Master Mix (Applied
Biosystems) or via TaqMan 50-nuclease methodology using ABI7700 (Applied
Biosystems) and TaqMan Universal PCR Master Mix (Applied Biosystems).
Expression was normalized to b-actin for mouse or RPS14 for human samples.
Sequences for the primers used are included in the Supplemental Experimen-
tal Procedures.
Analysis of Gene Expression in Papillomas
Skin papillomas were generated in FVB mice using a classical initiation/promo-
tion protocol (Collado et al., 2005). Papillomas and normal skin were used to
prepare total RNA using Trizol (Invitrogen) followed by additional purification
with RNeasy minikit (QIAGEN).
Immunohistochemical Analyses
Immunohistochemical analyses of CXCR1 and CXCR2 were performed in 30
PIN and paired prostate adenocarcinoma samples from properly consented
patients accrued by the New York University tissue bank (PI: Jonathan Mel-
amed, MD) as described in detail in the Supplemental Experimental Proce-
dures.
Human Chemokine and Cytokines Antibody Arrays
Human chemokine or human cytokine V arrays (Ray Biotech, Inc) were used
following the manufacturer’s instructions. After developing, films were
scanned and the images processed and quantified using ImageJ software
(National Institutes of Health). Intensity was normalized to internal positive
controls for comparison.
ELISA for IL-8 and GROa
The concentration of chemokines released to the supernatant was measured
via specific IL-8 or GROa ELISA (Quantikine ELISA Kit; R&D Systems).
Chromatin Immunoprecipitation
IMR-90 cells were harvested and processed for chromatin immunoprecipita-
tion. Sheared chromatin was sonicated together with 3 mg of RelA/p65 (sc-
109; Santa Cruz) or H3 antibodies (ab1791; Abcam). Immunoprecipitated
DNA was isolated using Chelex-100 (Bio-Rad) and analyzed by qRT-PCR.
Primers used are described in the Supplemental Experimental Procedures.
SUPPLEMENTAL DATA
Supplemental Data include sixteen figures and are available with this article
online at http://www.cell.com/cgi/content/full/133/6/1006/DC1/.
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